# Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout
Canonical URL: https://biopharmsignal.com/news/IVA/inventiva-announces-a-comprehensive-capital-structure-optimization-including-deb-a83cac35
Ticker: IVA
Company: Inventiva
Source: Inventiva
Published: 2026-06-02 12:29 EST
## Summary

Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“ MASH ”), today announced that it has entered into agreements for a comprehensive refinancing transaction, consisting of (i) the repayment in full of the existing European Investment Bank (the " EIB ") loan and the buyback of a portion of the warrants issued in favor of the EIB in connection with the loan (the " EIB Transactions "), (ii) a new debt financing with BlackRock and Claret Capital Partners of up to €130 million in committed tranches, subject to conditions, plus an additional uncommitted tranche of up to €20 million (the " Debt Financing Transaction ") with an initial aggregate drawdown of €75 million (corresponding to the drawdown of Tranche A and Tranche B of the Debt Financing), and (iii) an offering in the United States of 27,272,727 new American Depositary Shares (" ADSs "), each representing one new ordinary share of the Company with a nominal value of €0.01 (the " Ordinary Shares "), at an offering price of $4.40 per ADS (the " Equity Offering ", and together with the EIB Transactions and the Debt Financing Transaction, the " Combined Transaction ") 3 .

## Article Body
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“ MASH ”), today announced that it has entered into agreements for a comprehensive refinancing transaction, consisting of (i) the repayment in full of the existing European Investment Bank (the " EIB ") loan and the buyback of a portion of the warrants issued in favor of the EIB in connection with the loan (the " EIB Transactions "), (ii) a new debt financing with BlackRock and Claret Capital Partners of up to €130 million in committed tranches, subject to conditions, plus an additional uncommitted tranche of up to €20 million (the " Debt Financing Transaction ") with an initial aggregate drawdown of €75 million (corresponding to the drawdown of Tranche A and Tranche B of the Debt Financing), and (iii) an offering in the United States of 27,272,727 new American Depositary Shares (" ADSs "), each representing one new ordinary share of the Company with a nominal value of €0.01 (the " Ordinary Shares "), at an offering price of $4.40 per ADS (the " Equity Offering ", and together with the EIB Transactions and the Debt Financing Transaction, the " Combined Transaction ") 3 .
## Recent Company News
- 2026-07-09 20:20 EST — [Inventiva annonce la finalisation de la restructuration des BSA BEI à la suite de l'émission des Nouveaux BSA BEI](https://biopharmsignal.com/news/IVA/inventiva-annonce-la-finalisation-de-la-restructuration-des-bsa-bei-la-suite-de--60ee4494) — Source: Inventiva
- 2026-07-09 20:20 EST — [Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants](https://biopharmsignal.com/news/IVA/inventiva-announces-completion-of-the-eib-warrant-restructuring-with-the-issuanc-ea832ac9) — Source: Inventiva
- 2026-07-02 20:00 EST — [Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunie le 30 juin 2026](https://biopharmsignal.com/news/IVA/r-sultats-des-votes-de-l-assembl-e-g-n-rale-mixte-des-actionnaires-r-unie-le-30--623fc98c) — Source: Inventiva
- 2026-07-02 20:00 EST — [Results of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026](https://biopharmsignal.com/news/IVA/results-of-the-votes-of-the-combined-shareholders-general-meeting-of-june-30-202-4542eebe) — Source: Inventiva
- 2026-06-12 20:00 EST — [Inventiva annonce le Remboursement des Prêts BEI, le Rachat d'une partie des BSA BEI et l'émission des deux premières tranches dans le cadre du Nouveau Financement](https://biopharmsignal.com/news/IVA/inventiva-annonce-le-remboursement-des-pr-ts-bei-le-rachat-d-une-partie-des-bsa--76c5faf3) — Source: Inventiva
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)